Beyond Air Sells NeuroNOS Stake to Univo for Equity and Milestones

Beyond Air just made a move that traders need to watch closely. The company has signed a definitive agreement to sell its NeuroNOS stake to UNIVO Pharmaceutical Industries, and instead of cash upfront, Beyond Air is getting paid in equity and future milestone payments — a structure that bets big on Univo's success down the road.

Here's the headline number: Beyond Air will receive shares representing 19.99% of Univo's issued and outstanding share capital at closing. That's a meaningful ownership slice in a pharma company, and it ties Beyond Air's upside directly to how well Univo executes on the NeuroNOS asset going forward.

Read more Dow Jones Top Movers to Watch This Tuesday Session →

The milestone payment component adds another layer of potential value. If Univo hits pre-agreed development or commercial targets, Beyond Air collects additional payouts — meaning the total deal value isn't fixed. It could be worth far more than the equity alone if the drug program delivers.

For retail traders, the tradeable angle is straightforward: this deal transforms Beyond Air from an operator of the NeuroNOS program into a financially leveraged bystander. That's either a smart capital recycling move or a sign management wanted the asset off the books. Watch how the market prices that ambiguity at open.

Continue reading at GlobalNewswire.